“PO-75 | Network meta-analysis comparing efficacy and safety outcomes of atogepant, rimegepant, and galcanezumab in patients with episodic migraine after including CHALLENGE-MIG Trial: Jessica Ailani,1 Pranav Gandhi,2 Anjana Lalla,2 Peter McAllister,3 Tanya Bilchik,4 Stephanie Nahas,5 David Rowe,6 Cristiano Piron,6 Kari Kelton,6 Raffaello Masselli*, Rashmi Halker Singh7 | 1MedStar Health, Washington DC, USA; 2AbbVie, North Chicago, IL, USA; 3New England Institute for Neurology and Headache, Stamford, CT USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Department of Neurology, Thomas Jefferson University, Philadelphia, PA USA; 6Medical Decision Modeling Inc., Indianapolis, IN, USA; 7Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy. This individual has been added to this publication author by-line, with the permission of the original authors, for the express purpose of conducting the presentation at a local congress or in a local language. He did not contribute to the content of the publication”. (2025) Confinia Cephalalgica, 35(S1). doi:10.4081/cc.2025.15899.